Endocrine Abstracts

JOINT1401

Introduction: Long-acting growth hormone (LaGH) has been developed to improve treatment adherence and patient convenience compared to daily GH injections. In adults with growth hormone deficiency (GHD), LaGH therapy aims to restore physiological GH levels, supporting metabolic health, body composition, and overall well-being. While clinical trials have demonstrated the efficacy and safety of LaGH, real-world data on its use in adult patients remain limited.

Methods: The Investigating Significant Health Trends in Growth Hormone Treatments (INSIGHTS-GHT) registry is an ongoing, German multicenter, observational study designed to collect real-world evidence on the characteristics, treatment patterns, effectiveness, and safety of GH therapy in patients with GHD. Here, we provide an overview of adult patients receiving LaGH within the registry at an interim analysis, dated January 10^th, 2025, with a focus on baseline characteristics and initial treatment patterns.

Results: A total of 25 adult patients with GHD receiving LaGH therapy were included. The mean age at GHD diagnosis was 23.2 years (SD: 19.1; range: 0.8–60.8), while the mean age at LaGH initiation was 39.4 years (SD: 16.0; range: 18.3–73.9). Half of the patients (n = 12, 50.0%) had childhood-onset GHD. Regarding sex distribution, 9 patients (36.0%) were male, and 16 (64.0%) were female. The majority had organic GHD (n = 21, 84.0%), while 4 patients (16.0%) had idiopathic GHD. Most patients (n = 24, 96.0%) transitioned from prior daily GH therapy, with a mean duration of previous treatment of 12.8 years (SD: 8.0). The initial LaGH dose was below the recommended level in 6 patients (31.6%), at the recommended level in 11 patients (57.9%), and above the recommended level in 2 patients (10.5%).

Conclusion: This analysis from the INSIGHTS-GHT registry provides first real-world insights into the characteristics and treatment patterns of adults receiving LaGH. The data show that most patients had organic GHD, with a significant proportion transitioning from prior daily GH therapy. While the majority initiated LaGH at the recommended dose, some started at lower or higher doses, highlighting variability in treatment approaches. The number of patients in the INSIGHTS registry with LAGH therapy can be seen as an indication of its acceptance by patients and prescribers. Since the analyses are continuously updated, INSIGHTS-GHT offers an excellent research platform for investigating these and other aspects of somatotropin therapy.